Your Messages Inbox
Your Article Summary
See Latest ArticlesShire Reports Tolerability and Clinical Effects Results of DAYTRANA from Study in Adolescents with ADHD
Shire, 11/02/09
Shire plc, the global specialty biopharmaceutical company, announced findings at a major medical meeting from a Phase IIIb study of the tolerability and effectiveness of DAYTRANA in adolescents aged 13 to 17 years diagnosed with Attention–Deficit/Hyperactivity Disorder. In addition, data regarding the pharmacokinetic profile of DAYTRANA in children and adolescents was also presented. DAYTRANA, the first and only patch for the treatment of ADHD, is indicated for use in children aged 6 to 12 years with the disorder.
Today in Marketing/Media/ROI...keeping you current
Receive free subspecialty "5-minute updates" via email
Chugai Revises Corporate Advertisement for First Time in Four Years
Chugai Pharmaceutical Co., 11/25/09
Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09
Medtronic Introduces 3D Recon Service to Enhance Endovascular Treatment of Aortic Aneurysms
Medtronic, 11/20/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
Novartis, 11/25/09
Bayer CropScience signs Agreement with GVK Biosciences on early-stage research projects
BayNews International, 11/25/09
Reports Rate Ambulatory EHR Software
HealthDataManagement, 11/25/09
Article Search
Sponsor